FFA
LIMN

Farther Finance Advisors’s Liminatus Pharma LIMN Stock Holding History

Farther Finance Advisors’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– -$2 – 6152
2026
Q1 		– Sell
-1
Closed -$27 – 5741
2025
Q4 		$19 Hold
1
– – ﹤0.01% 5398
2025
Q3 		$52 Buy
+1
New +$216 ﹤0.01% 4869

Other funds holding LIMN

CCA
Cygnus Capital Advisors Atlanta, Georgia $147M AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Farther Finance Advisors's LIMN Position: Q2 2026 in Review

Farther Finance Advisors held its Liminatus Pharma (LIMN) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6152.

Farther Finance Advisors first reported a position in LIMN in Q3 2025 and has held it in 2 quarters since. The position peaked at $52 in Q3 2025. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Farther Finance Advisors held 0 shares of Liminatus Pharma worth $0 as of Q2 2026.
  • Farther Finance Advisors left its Liminatus Pharma share count unchanged in Q2 2026.
  • Liminatus Pharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #6152 holding.
  • Farther Finance Advisors first reported a position in Liminatus Pharma in Q3 2025 and has held it in 2 quarters since.
  • Farther Finance Advisors's Liminatus Pharma position peaked at $52 in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.